As a pre-clinical CRO Heidelberg Pharma offers explorative pharmacology, drug metabolism and pharmacokinetics (DMPK) analysis and molecular biology. As a drug development company Company concentrates on combining the targeting properties of antibodies with the effectiveness of an ultra-potent toxin with antibody-drug conjugates (ADC), that are more effective against cancer. Their antibody-drug conjugates (ADC) project project has achieved the status of a technology platform, potentially leading to multiple 2nd generation ADCs for treatment of different tumor entities.

Company was acquired by Wilex AG